Processa Pharma Files DEF 14A, Details Exec Pay
Ticker: PCSA · Form: DEF 14A · Filed: May 12, 2025 · CIK: 1533743
| Field | Detail |
|---|---|
| Company | Processa Pharmaceuticals, Inc. (PCSA) |
| Form Type | DEF 14A |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, corporate-governance, def-14a
Related Tickers: PCSA
TL;DR
Processa Pharma's DEF 14A is out, showing exec pay for 2024. Check it for governance details.
AI Summary
Processa Pharmaceuticals, Inc. filed a DEF 14A on May 12, 2025, detailing executive compensation and corporate governance for the fiscal year ending December 31, 2024. The filing includes information on compensation for key personnel such as George Ng and David Young, who are identified as members of the board or executive team. The company, formerly known as Heatwurx, Inc., is in the pharmaceutical preparations industry.
Why It Matters
This filing provides transparency into how Processa Pharmaceuticals compensates its top executives and outlines corporate governance practices, which can influence investor confidence and company strategy.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures, but they can reveal information about executive compensation and corporate governance that may impact investor perception and stock performance.
Key Numbers
- 2024 — Fiscal Year End (The period for which executive compensation and corporate governance are detailed.)
- 20250512 — Filing Date (The date Processa Pharmaceuticals, Inc. submitted this DEF 14A filing.)
Key Players & Entities
- Processa Pharmaceuticals, Inc. (company) — Filer of the DEF 14A
- George Ng (person) — Executive/Board Member
- David Young (person) — Executive/Board Member
- Heatwurx, Inc. (company) — Former company name
- 2834 (dollar_amount) — Standard Industrial Classification Code for Pharmaceutical Preparations
FAQ
What is the total compensation reported for George Ng and David Young for the fiscal year 2024?
The provided filing excerpt does not contain specific dollar amounts for the total compensation of George Ng and David Young for the fiscal year 2024. It only indicates their roles as members and the reporting periods.
What were the primary reasons for the name change from Heatwurx, Inc. to Processa Pharmaceuticals, Inc.?
The provided filing excerpt states the former company name was Heatwurx, Inc. and the date of the name change was 20111028, but it does not detail the reasons for this change.
What is the business address of Processa Pharmaceuticals, Inc.?
The business address for Processa Pharmaceuticals, Inc. is 7380 Coca Cola Drive, Suite 106, Hanover, MD 21076.
What is the Standard Industrial Classification (SIC) code for Processa Pharmaceuticals, Inc.?
The Standard Industrial Classification code for Processa Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
When was Processa Pharmaceuticals, Inc. incorporated?
The filing indicates the state of incorporation is DE (Delaware), but the specific incorporation date is not provided in this excerpt.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on May 12, 2025 by George Ng regarding Processa Pharmaceuticals, Inc. (PCSA).